Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

FIXED ASSETS

FIXED ASSETS

12 Months Ended

Dec. 31, 2022

FIXED ASSETS

FIXED ASSETS

4. FIXED ASSETS

Fixed assets consisted of the following as of December 31:


	2022		2021

Office and laboratory equipment	$	797,278	$	575,370
Computer software		4,000		4,000
Leasehold improvements		309,897		309,897
Total fixed assets		1,111,175		889,267
Less– accumulated depreciation and amortization		(692,534)		(544,776)
Fixed assets, net	$	418,641	$	344,491

For the years ended December 31, 2022 and 2021, the Company recorded approximately $148,000 and $150,000 of depreciation and amortization expense, respectively.